 The application was then resubmitted in 1987, and the USPTO again rejected it.After receiving expert testimony from Omura's "associates in clinical fields and basic sciences, both in Japan and the United States" regarding BDORT, the USPTO issued in 1993.The fact that a patent was granted to the BDORT has been cited as an example of 'high weirdness' by one firm of patent attorneys.